Low-Dose Ketamine Eligibility: Who Qualifies for Treatment

Low-dose ketamine eligibility depends on your diagnosis, treatment history, and results from a medical and psychiatric screening, there is no single national standard, because only esketamine (Spravato), the FDA-approved nasal spray formulation of ketamine, has defined regulatory eligibility criteria, and only for treatment-resistant depression. All other low-dose ketamine protocols, intravenous (IV), intramuscular (IM), and sublingual dosing, are prescribed off-label, based on a prescriber's clinical judgment and published consensus guidance rather than an FDA-set standard.

If you're researching whether you might qualify, most clinics use a similar general framework: confirm a diagnosis with supporting evidence, rule out medical and psychiatric contraindications, and document that standard treatments haven't worked well enough. This is educational information, not a personal medical clearance, eligibility is ultimately determined by a licensed prescriber who reviews your specific history.

Diagnosis and Treatment History Requirements

Most low-dose ketamine programs for depression require a documented diagnosis of major depressive disorder (MDD) or treatment-resistant depression (TRD), commonly defined in the research literature as an inadequate response to at least two adequate trials of different antidepressant medications at an appropriate dose and duration. A 2017 consensus statement from a multidisciplinary group of researchers, published in JAMA Psychiatry, recommended reserving ketamine for patients who meet this treatment-resistance threshold and have been evaluated by a psychiatrist, rather than offering it as a first-line option (Sanacora et al., 2017).

Some clinics also screen candidates for chronic pain conditions with published low-dose ketamine evidence, such as complex regional pain syndrome (CRPS), though evidence strength varies by condition and is generally lower than for depression. Anxiety and post-traumatic stress disorder are sometimes treated off-label as well, but published data supporting formal eligibility criteria for those indications is more limited. For a closer look at how clinicians weigh these factors together, see this guide to patient selection criteria for ketamine treatment.

Special Populations and Additional Considerations

Eligibility screening looks different for certain groups. Older adults often need closer review of cardiovascular status and slower dose titration because of higher rates of hypertension and polypharmacy; see this guide to ketamine therapy for older adults safety for what that involves. Patients on multiple medications for late-life depression face additional screening for drug interactions, covered in low-dose ketamine for late-life depression with multiple medications.

Bipolar disorder requires particular caution: ketamine can, in some patients, trigger a manic or hypomanic episode, so clinicians typically screen for bipolar spectrum illness before starting treatment and monitor closely if it proceeds. Read more about this specific risk in our overview of mania risk in bipolar disorder. Researchers are also studying whether biological markers can help predict who is more likely to respond, though this work remains investigational and isn't yet part of standard eligibility screening, see current findings on biomarkers of ketamine response.

If eligibility is confirmed, ongoing monitoring matters as much as the initial screen. Many programs now offer telehealth ketamine protocols with structured check-ins, and ask patients to track symptoms between treatments so the prescriber can adjust the plan over time.